Alyeska Investment Group
CARM

Alyeska Investment Group’s Carisma Therapeutics CARM Stock Holding History

Alyeska Investment Group’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-70,000
Closed -$785K – 488
2020
Q1 		$785K Hold
70,000
– – 0.02% 314
2019
Q4 		$1.46M Hold
70,000
– – 0.02% 312
2019
Q3 		$1.64M Hold
70,000
– – 0.02% 304
2019
Q2 		$2.1M Buy
+70,000
New +$2.1M 0.03% 317

Other funds holding CARM

TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Alyeska Investment Group's CARM Position: Q4 2018 in Review

Alyeska Investment Group sold out of Carisma Therapeutics (CARM) in Q4 2018, closing a stake of 2,665 shares — an estimated $115K sold.

Alyeska Investment Group first reported a position in CARM in Q2 2018 and held it in 2 quarters. The position peaked at $1.48M in Q2 2018. 48 funds tracked by Wall St. Rank hold CARM as of Q4 2018.

  • Alyeska Investment Group reported no remaining Carisma Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 2,665 Carisma Therapeutics shares in Q4 2018, an estimated $115K.
  • Alyeska Investment Group first reported a position in Carisma Therapeutics in Q2 2018 and held it in 2 quarters.
  • Alyeska Investment Group's Carisma Therapeutics position peaked at $1.48M in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2018.

Based on Alyeska Investment Group's 13F filing for Q4 2018, filed 14 Feb 2019.